56亿市值三元生物：上市后业绩变脸却豪掷19亿元理财，慷慨分红背后现金管理收益成利润重要来源！

Core Viewpoint - San Yuan Bio plans to use up to 1.9 billion RMB of temporarily idle funds for cash management, despite its relatively small market capitalization of approximately 5.6 billion RMB, supported by substantial cash reserves from its IPO fundraising [1][2]. Group 1: Financial Performance - San Yuan Bio raised a total of 3.686 billion RMB during its IPO, with over 2 billion RMB allocated for working capital, resulting in cash and cash-like assets exceeding 3 billion RMB [1][8]. - The company's revenue has significantly declined post-IPO, with figures of 1.675 billion RMB in 2021 dropping to 675 million RMB, 500 million RMB, and 713 million RMB in 2022, 2023, and 2024 respectively, and a further decline of 7.54% in the first three quarters of 2025 [3]. - Net profit also saw a drastic decrease, from 535 million RMB in 2021 to 164 million RMB, 56 million RMB, and 105 million RMB in the following years, with a 16.80% decline in the first three quarters of 2025 [4]. Group 2: Profitability Metrics - The gross profit margin fell sharply from over 40% in the years leading up to the IPO to 14.06%, 3.05%, and 11% in the years following, with a slight recovery to 16.15% in the first three quarters of 2025 [3]. - Return on equity (ROE) also plummeted from 55.52% in 2019 to 3.8%, 1.23%, and 2.31% in the subsequent years, with a further drop to 1.53% in the first three quarters of 2025 [4]. Group 3: Dividend Policy - Despite the decline in performance, San Yuan Bio has been generous with dividends, distributing a total of 708 million RMB since its IPO, which exceeds the total net profit of 392 million RMB earned since 2022 [5][6]. - The company announced a dividend of 17.5 RMB per 10 shares for 2025, resulting in a dividend yield of 6.2% based on the closing price of 28.21 RMB on January 26 [6]. Group 4: Cash Management and Fund Utilization - San Yuan Bio's substantial cash and cash-like assets, totaling approximately 3.01 billion RMB, have enabled its high dividend payouts, with significant portions derived from investment income [7]. - The company has utilized 2.08 billion RMB of IPO funds for working capital, significantly exceeding the planned amount, while a large portion of the IPO funds remains unutilized, totaling 1.278 billion RMB as of mid-2025 [8].